Improvement of a 1D Population Balance Model for Twin-Screw Wet Granulation by Using Identifiability Analysis.
PAT
continuous manufacturing
formulation
granulation
granules
identifiability
particle size distributions
population balance modeling
process modeling and simulation
wet granulation
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
11 May 2021
11 May 2021
Historique:
received:
26
03
2021
revised:
28
04
2021
accepted:
01
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Recently, the pharmaceutical industry has undergone changes in the production of solid oral dosages from traditional inefficient and expensive batch production to continuous manufacturing. The latest advancements include increased use of continuous twin-screw wet granulation and application of advanced modeling tools such as Population Balance Models (PBMs). However, improved understanding of the physical process within the granulator and improvement of current population balance models are necessary for the continuous production process to be successful in practice. In this study, an existing compartmental one-dimensional PBM of a twin-screw granulation process was improved by altering the original aggregation kernel in the wetting zone as a result of an identifiability analysis. In addition, a strategy was successfully applied to reduce the number of model parameters to be calibrated in both the wetting zone and kneading zones. It was found that the new aggregation kernel in the wetting zone is capable of reproducing the particle size distribution that is experimentally observed at different process conditions as well as different types of formulations, varying in hydrophilicity and API concentration. Finally, it was observed that model parameters could be linked not only to the material properties but also to the liquid to solid ratio, paving the way to create a generic PBM to predict the particle size distribution of a new formulation.
Identifiants
pubmed: 34064771
pii: pharmaceutics13050692
doi: 10.3390/pharmaceutics13050692
pmc: PMC8151179
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Pharmaceutics. 2018 Jun 01;10(2):
pubmed: 29857576
Int J Pharm. 2017 Aug 30;529(1-2):678-693
pubmed: 28720539
PLoS One. 2011;6(11):e27755
pubmed: 22132135
Int J Pharm. 2019 Jul 20;566:352-360
pubmed: 31170476
Int J Pharm. 2017 Mar 15;519(1-2):165-177
pubmed: 28099877
Int J Pharm. 2020 Feb 25;576:119004
pubmed: 31935475
Int J Pharm. 2015 Feb 1;479(1):171-80
pubmed: 25562758
Int J Pharm. 2020 Dec 15;591:120018
pubmed: 33122111
Nat Methods. 2020 Mar;17(3):261-272
pubmed: 32015543
Pharmaceutics. 2020 Nov 27;12(12):
pubmed: 33260899
Pharm Dev Technol. 2019 Jan;24(1):105-117
pubmed: 29336653
Int J Pharm. 2020 Mar 15;577:119068
pubmed: 31981703
Int J Pharm. 2015 Dec 30;496(1):3-11
pubmed: 26232701